Last reviewed · How we verify

American Genomics, LLC — Portfolio Competitive Intelligence Brief

American Genomics, LLC pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Proparacaine Ophthalmic Proparacaine Ophthalmic marketed Local anesthetic (ester) Voltage-gated sodium channels Ophthalmology
AG-920 AG-920 phase 3 Nucleoside analog Ribonucleotide reductase Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Centre Hospitalier Universitaire Saint Pierre · 1 shared drug class
  2. City of Hope Medical Center · 1 shared drug class
  3. Cooperative Study Group A for Hematology · 1 shared drug class
  4. Genzyme, a Sanofi Company · 1 shared drug class
  5. Hospices Civils de Lyon · 1 shared drug class
  6. Innovent Biologics (Suzhou) Co. Ltd. · 1 shared drug class
  7. Nova Scotia Health Authority · 1 shared drug class
  8. Actuate Therapeutics Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for American Genomics, LLC:

Cite this brief

Drug Landscape (2026). American Genomics, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/american-genomics-llc. Accessed 2026-06-10.

Related